Chemoproteomics Discovery of a Central Nervous System-Penetrant Covalent Inhibitor of PIKfyve
ACS Chemical Biology · 06.11.2026
DOI: 10.1021/acschembio.6c00795 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 06.11.2026. Verfasst von Antony J Burton und 19 weiteren Autor:innen. Beteiligte Einrichtung: Dunad Therapeutics , The Officers' Mess, Duxford, CambridgeCB22 4QH, UK. Die Arbeit nennt 52 Literaturangaben.
Abstract (Originalsprache)
PIKfyve is a lipid kinase involved in regulating protein clearance mechanisms and is a promising target for the treatment of neurodegenerative diseases. We present the discovery and optimization of a central nervous system (CNS)-penetrant covalent PIKfyve inhibitor, DUN’058, which achieves sustained target occupancy in vivo. Covalent screening hits, identified from chemoproteomics experiments performed in live cells, were rapidly optimized to deliver a brain-penetrant covalent inhibitor of PIKfyve. This covalency centred approach employed a suite of mass spectrometry, biochemical and in vivo assays to optimize compound potency, selectivity, and CNS permeability. The target nucleophile, cysteine 1970, is on a flexible loop that appears distal from the kinase active site, highlighting the power of chemoproteomics screening to identify novel nucleophilic amino acids for covalent modification. DUN’058 achieves efficient covalency at the target cysteine, as well as highly selective covalent and reversible selectivity profiles. Covalent PIKfyve inhibition results in modulation of downstream pathway activity, including activation of the transcription factor TFEB, upregulation of protein clearance pathways, and increased GPNMB transcription and secretion of exosome markers. When dosed in vivo, DUN’058 achieves sustained target occupancy in the brains of mice long after systemic compound clearance. The development of DUN’058 is a demonstration of chemoproteomics-based discovery for a high value CNS target, providing an orally bioavailable and covalent PIKfyve inhibitor.
Autor:innen und Institutionen
- Dunad Therapeutics , The Officers' Mess, Duxford, CambridgeCB22 4QH, UK.
- Dunad Therapeutics , CIC Cambridge, 1 Broadway, Cambridge, Massachusetts02142, United States.
- Department of Chemistry and Biomolecular Sciences, University of OttawaK1N 6N5, Canada.
ORCID-Profile: Antony J Burton, Louis S Chupak, Mirco Meniconi, Ryan Mulhern, Elizabeth W Sorensen, Ruben Tommasi, Jeffrey W Keillor, Laura D'Agostino
Zitieren
APA
Burton, A. J., Chupak, L. S., Davis, A. J., Mady, A. S. A., Meniconi, M., Teobald, B., Dorsey, B. W., Byrne, L. R., Mulhern, R., Lundeen, B., Sorensen, E. W., Patel, B., Brennan, S., Kormocha, D., Tommasi, R., Simpson, G. L., Keillor, J. W., D'Agostino, L., Penebre, E., & Huang, P. S. (2026). Chemoproteomics Discovery of a Central Nervous System-Penetrant Covalent Inhibitor of PIKfyve. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00795
Vancouver
Burton AJ, Chupak LS, Davis AJ, Mady ASA, Meniconi M, Teobald B, et al. Chemoproteomics Discovery of a Central Nervous System-Penetrant Covalent Inhibitor of PIKfyve. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00795
BibTeX
@article{Burton2026,
author = {Burton, Antony J and Chupak, Louis S and Davis, Alison J and Mady, Ahmed S A and Meniconi, Mirco and Teobald, Barry and Dorsey, Bryan W and Byrne, Lauren R and Mulhern, Ryan and Lundeen, Berent and Sorensen, Elizabeth W and Patel, Bharti and Brennan, Sean and Kormocha, Dhiraj and Tommasi, Ruben and Simpson, Graham L and Keillor, Jeffrey W and D'Agostino, Laura and Penebre, Elayne and Huang, Pearl S},
title = {Chemoproteomics Discovery of a Central Nervous System-Penetrant Covalent Inhibitor of PIKfyve},
journal = {ACS Chemical Biology},
year = {2026},
doi = {10.1021/acschembio.6c00795}
}
EUVIMED